Recital 15, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

In forcesince 16 Apr 2014

In order to improve treatments available for vulnerable groups such as frail or older people, people suffering from multiple chronic conditions, and people affected by mental health disorders, medicinal products which are likely to be of significant clinical value should be fully and appropriately studied for their effects in these specific groups, including as regards requirements related to their specific characteristics and the protection of the health and well-being of subjects belonging to these groups.